iPSアカデミアジャパン株式会社 Accredited TLO

iPS Academia Japan, Inc.

iPS ACADEMIA JAPAN

Licensing Program Outline FY2026

IP ECOSYSTEM & LICENSE POLICY

iPS Academia Japan serves as a central bridge linking academia and industry through licensing activities covering patents from foundational iPS cell technologies to applied and related technologies and fields.

Contents

03 IP ecosystem & license policy

04 iPS cell-related technologies


05 Licensing programs

08 Examples of licensing cases

09 Financial terms

10 Others

LICENSING POLICY



License Policy

iPS Academia Japan manages intellectual properties derived from iPS cell research through licensing in accordance with two key guidelines established by the Council for Science and Technology Policy – namely, the "Guidelines for Research Licenses for Intellectual Property Rights Stemming from Government-Funded R&D at Universities, etc." (May 23, 2006) and the "Guidelines for Facilitating the Use of Research Tool Patents in the Life Sciences (March 1, 2007)." In this way, we make the intellectual properties broadly available to the industrial and scientific communities under the policies of iPS Academia Japan.

1 Not-for-profit institutions

Not-for-profit institutions may use intellectual properties for non-commercial research or educational purposes on a royalty-free basis without entering into a license agreement. However, not-for-profit institutions are not permitted to provide iPS cells – including differentiated cells derived from iPS cells – to for-profit organizations without the prior consent of iPS Academia Japan, Inc.

2 For-profit entities

Licenses are, in principle, granted on a non-exclusive basis to for-profit entities at fair and reasonable royalty rates. Under specific conditions, however, an exclusive license agreement may be considered for intellectual properties related to iPS cell technologies, excluding the core platform technologies.

iPS CELL-RELATED TECHNOLOGIES


Portfolio

Diversifying iPS Cell Technologies Open New Possibilities for Healthcare Innovation

Technologies beyond iPS cell reprogramming—including cell differentiation and drug discovery—now account for a significant and growing share of our portfolio, marking a clear shift from our initial focus. This shift reflects the evolution of iPS cell technology into a platform enabling new forms of medicine to emerge in multiple areas.


Please use the QR code on the left to access our iPS cell-related license portfolio.
https://ips-cell.net/e/patent/

Central Interface of iPS cell-related Technologies



As of September 2026

Licensing Across Diverse Sectors



As of September 2026

Our license agreements span a diverse range of fields, including drug discovery and regenerative medicine, reflecting the global spread of iPS cell-related technologies.
These developments demonstrate that the future of regenerative medicine that can be unlocked by iPS cells is steadily becoming a reality, and the use of iPS cell technologies is also expanding across various industries.

A STRUCTURED LICENSING PROGRAM

Licensing Program Framework

iPS Academia Japan provides a fair and structured licensing framework that supports each stage from early research to commercialization.

Early Research → Commercialization

For collaborative or contract research, prior approval from iPS Academia Japan is required, along with appropriate licensing for collaborators or contractors.

Internal Research License

iPS cell-related research activities including internal research and collaborative research for regenerative medicine products and research-use-only (RUO) products and services

Key word: Identification, Pre-clinical, Internal Research

*For internal research beyond the scope of licensed products or services, a separate license is obtained.

Stage Transition

Manufacturing, Sales and Service License (Research Use Only (RUO))

RUO product and service development after target identification or iPS cell sourcing (non-clinical use)

Key word: Product Development, Research Tool, Non-clinical

Stage Transition

Therapeutic Use License *

Therapeutic development initiated upon a clinical trial notification after pre-clinical studies (clinical use)

Key word: Clinical, Regenerative Medicine, Drug Discovery

Clinical Trial Notification

NDA (New Drug Application)

*A Therapeutic Use License should be obtained before filing a clinical trial notification.


The figures in the "Licensing Programs" section on page 5 and 6 illustrate the overall structure and flow of our licensing programs. Specific terms and conditions are determined on a case-by-case basis.

For further information, please use the QR code on the left to access our Contact Us form or contact our Licensing team directly.

A STRUCTURED LICENSING PROGRAM 1

Licensing Decision Flow

How licensing requirements are determined based on use and cell sourcing
(This flow chart outlines the process for determining licensing requirements. Final determinations should be made in conjunction with the Licensing Matrix on page 7.)



"Screening" refers primarily to a series of activities conducted for the purpose of exploration and identification of substances that are candidates for active ingredients used in products intended for the treatment, prevention, or diagnosis of diseases, as well as for the maintenance or improvement of human or animal health.

For further information, including the specific meanings of "exploration" and "identification" as well as examples of activities that do or do not constitute "Screening," please refer to our Q&A section on our website.

A STRUCTURED

LICENSING PROGRAM

2

Scope of Licensed Activities

A structured licensing framework from research to commercialization
(This matrix outlines the fundamental licensing framework. Final determinations should be made in conjunction with the Licensing Decision Flow on page 6.)

	License Agreement	Programs	Exploration & Identification (Screening)	Production	Internal Research	Commercialization	Cell Sourcing
Internal Research License	No	—	—	—	✓	—	Purchased from for-profit organizations*1
	Yes	Contract Type ①	—	—	✓	—	Sourced from not-for-profit organizations
	Yes	Contract Type ②	—	✓	✓	—	Produced in-house or sourced from not-for-profit organizations
	Yes	Contract Type ③	✓	—	✓	—	Sourced from not-for-profit or for-profit organizations
	Yes	Contract Type ④	✓	✓	✓	—	Sourced from not-for-profit or for-profit organizations
Manufacturing, Sales and Service License (RUO)	Yes	Manufacturing, Sales and Service License	✓ / —*2	✓ / —*2	—*3	✓	Sourced from not-for-profit or for-profit organizations, or produced in-house within the scope of licensed activities
Therapeutic Use License	Yes	Therapeutic Use License	✓ / —*2	✓ / —*2	✓*3	✓	Sourced from not-for-profit or for-profit organizations, or produced in-house within the scope of licensed activities

In the figures above, "✓" indicates licensed activities, and "—" indicates out-of-scope activities.

"Screening" refers primarily to a series of activities conducted for the purpose of exploration and identification of substances that are candidates for active ingredients used in products intended for the treatment, prevention, or diagnosis of diseases, as well as for the maintenance or improvement of human or animal health.

For further information, including the specific meanings of "exploration" and "identification" as well as examples of activities that do or do not constitute "Screening," please refer to our Q&A section on our website.

*1 The use of iPS cells purchased from commercial providers under appropriate licensing does not require a license for internal research. Screening using these cells for target identification requires either Contract Type 3 or 4 depending on the cell sourcing.

*2 The scope of licensed activities, including production of iPS cells and screening, is determined on a case-by-case basis, depending on the nature of licensed products, services, or other relevant factors.

*3 Pre-clinical research activities beyond the scope of licensed products and services require a separate license in addition to RUO licensing.

EXAMPLES

EXAMPLES OF LICENSING CASES

Case 1 Testing Equipment Manufacturer

A testing equipment manufacturer plans to obtain iPS cells from a domestic not-for-profit organization for internal research and development of its automated iPS cell culture system.
This case requires “Contract Type 1.”

→ Contract Type 1

Case 2 Pharmaceutical Manufacturer

A pharmaceutical manufacturer plans to use iPS cells established via its own proprietary protocols for internal research and development of differentiation methods for specific cell types, tissues, and organs.
This case requires “Contract Type 2.”

→ Contract Type 2

Case 3 Pharmaceutical Manufacturer

A pharmaceutical manufacturer plans to differentiate iPS cells that were either obtained from a not-for-profit organization or purchased from our for-profit licensee into target cell types using its in-house protocols for internal research and development including exploration or identification of substances that are candidates for active ingredients.
This case requires “Contract Type 3.”

→ Contract Type 3

Case 4 Pharmaceutical Manufacturer

A pharmaceutical manufacturer plans to differentiate iPS cells established via its own proprietary protocols into target cell types also using its in-house protocols for internal research and development including exploration or identification of substances that are candidates for active ingredients.
This case requires “Contract Type 4.”

→ Contract Type 4

Case 5 Reagent Manufacturer

A reagent manufacturer plans to manufacture and market research use only tools such as iPS cell-derived differentiated cells or iPS cell reprogramming kits using its in-house protocols. This case requires a “Manufacturing, Sales, and Service License.”

→ Manufacturing, Sales and Service License (RUO)

Case 6 Pharmaceutical Manufacturer

A pharmaceutical manufacturer plans to advance human iPS cell-based regenerative medicine products through clinical development with the goal of future commercialization. This case requires a “Therapeutic Use License.”

→ Therapeutic Use License

Case 7 Reagent Manufacturer

A reagent manufacturer plans to obtain iPS cells from a distributor properly licensed by iPS Academia Japan for internal research and development of its automated iPS cell culture system. No contract agreement with iPS Academia Japan is necessary in this case.

→ No contract required.

For further information, including the specific meanings of “exploration” and “identification” as well as examples of activities that do or do not constitute “Screening,” please refer to our Q&A section on our website using the QR code below.

“Screening” refers primarily to a series of activities conducted for the purpose of exploration and identification of substances that are candidates for active ingredients used in products intended for the treatment, prevention, or diagnosis of diseases, as well as for the maintenance or improvement of human or animal health.

FINANCIAL TERMS

Standard Financial Terms

This section outlines the standard financial framework for non-exclusive licensing of core iPS cell reprogramming patents, including technologies related to episomal vectors for each differentiated cell type. Specific financial terms are determined on a case-by-case basis, depending on factors such as the contract type or the number of licensed cell types, as well as the scope of licensed products and services.

Internal Research License

Use of iPS cells in pre-clinical research

Contract Type 1

- ✕ Production
- ✕ Exploration & Identification (Screening)

Sourced from not-for-profit organizations (iPS cells and their derivatives)

Large entity	US$ 14 K
Medium entity	US$ 11 K
Small entity *1	US$ 7 K

/year

Contract Type 2

- ○ Production
- ✕ Exploration & Identification (Screening)

Produced in-house or sourced from not-for-profit organizations (iPS cells and their derivatives)

Large entity	US$ 24 K
Medium entity	US$ 20 K
Small entity *1	US$ 12 K

/year

Contract Type 3

- ✕ Production
- ○ Exploration & Identification (Screening)

Sourced from not-for-profit or for-profit organizations (iPS cells and their derivatives)

Large entity	US$ 48 K
Medium entity	US$ 38 K
Small entity *1	US$ 24 K

/year

Contract Type 4

- ○ Production
- ○ Exploration & Identification (Screening)

Sourced from not-for-profit or for-profit organizations, or produced in-house within the scope of licensed activities (iPS cells and their derivatives)

Large entity	US$ 84 K
Medium entity	US$ 67 K
Small entity *1	US$ 42 K

/year

Therapeutic Use License

Use of iPS cells in clinical development and therapeutic applications

Fees and Royalties	SSE *1	Non-SSE
Upfront fee	US$13K	US$60K
Annual maintenance fee [until NDA approval]	US$12K	US$25K
Milestone payments on first IND applications in each of 3 areas *2	US$41K [in total of 3 areas]	US$130K [in total of 3 areas]
Milestone payments on first NDA applications in each of 3 areas *2	US$250K [in total of 3 areas]	US$295K [in total of 3 areas]
Milestone payment on achievement of sales total US$100M	US$400K	
Milestone payment on achievement of sales total US$500M	US$700K	
Running royalties	1.5% of sales of final products	
Annual minimum royalties [after NDA approval]	US$20K	US$25K

*Financial terms are determined on a case-by-case basis, depending on the scope and nature of licensed activities under each agreement.
- This reflects the minimum licensing scope, covering only a single country and core iPS cell reprogramming patents.
- Entity sizes are determined based on our internal criteria.

*1 A Small and Start-up Entity (SSE) is an entity that was founded within the last 10 years, employs 50 or fewer people, and has received no more than US$20 million in total investment.
*2 The three areas are North America, Europe, and the rest of the world.

FINANCIAL TERMS

OTHERS

Manufacturing, Sales, and Service License

Use of iPS cells for providing research-use-only products and related services involving these products

Please use the QR code on the right for further information on financial terms applicable to the use of iPS cells for marketing RUO products and related services involving such products under the Manufacturing, Sales, and Service License.

For Related and Applied Technologies

The framework in this section applies solely to licensing of core iPS cell reprogramming patents and does not cover financial terms applicable to related and applied technologies.
For further information, please use the QR code on the right to access our Contact Us form or contact our Licensing team directly.

iPS Academia Japan, Inc.

606-8501
Room 207, International Science Innovation Building East Wing
Kyoto University, Kyoto Japan
TEL075-754-0625/FAX075-761-3577

Corporate site